W tym dziale chcemy stworzyć wyczerpującą bibliografię publikacji na temat psychodelików. Zawiera ona wszystkie źródła, jakie pojawiły się w naszych artykułach, a także wiele innych, dodanych przez naszych czytelników.

Możesz pobrać poszczególne pozycje w formacie RIS, aby zaimportować je do swojego programu referencyjnego, klikając link (CITE). My używamy i polecamy Zotero. Jeśli uważasz, że brakuje tutaj jakiegoś tytułu, wypełnij ten formularz. Prosimy o podanie referencji w formacie APA oraz dołączenie identyfikatora DOI.

Wyszukaj artykuł:

thinking

Bibliografia:

Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021). Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacology & Translational Science, 4(2), 543–552. https://doi.org/10.1021/acsptsci.1c00018 Cite
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182–1190. https://doi.org/10.1177/0269881115609019 Cite
Bouso, J. C., Ona, G., Santos, R. G. D., & Hallak, J. E. C. (2021). Psychedelic Medicines in Major Depression: Progress and Future Challenges. Major Depressive Disorder, 515–533. https://doi.org/10.1007/978-981-33-6044-0_26 Cite
Carhart-Harris, R. L., Erritzoe, D., Haijen, E., Kaelen, M., & Watts, R. (2018). Psychedelics and connectedness. Psychopharmacology, 235(2), 547–550. https://doi.org/10.1007/s00213-017-4701-y Cite
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8. https://doi.org/10.3389/fnhum.2014.00020 Cite
Castro Santos, H., & Gama Marques, J. (2021). What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomedical Journal, 6(1), e128. https://doi.org/10.1097/j.pbj.0000000000000128 Cite
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology, 6(3), 193–213. https://doi.org/10.1177/2045125316638008 Cite
Dressler, H. M., Bright, S. J., & Polito, V. (2021). Exploring the relationship between microdosing, personality and emotional insight: A prospective study. Journal of Psychedelic Studies, 1(aop). https://doi.org/10.1556/2054.2021.00157 Cite
Fadiman, J., & Korb, S. (2019). Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. Journal of Psychoactive Drugs, 51(2), 118–122. https://doi.org/10.1080/02791072.2019.1593561 Cite
Forstmann, M., & Sagioglou, C. (2020). How psychedelic researchers’ self-admitted substance use and their association with psychedelic culture affect people’s perceptions of their scientific integrity and the quality of their research. Public Understanding of Science, 0963662520981728. https://doi.org/10.1177/0963662520981728 Cite
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021). Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology, 238(2), 341–354. https://doi.org/10.1007/s00213-020-05719-1 Cite
Gard, D. E., Pleet, M. M., Bradley, E. R., Penn, A., Gallenstein, M. L., Riley, L. S., DellaCrosse, M., Garfinkle, E., Michalak, E. E., & Woolley, J. D. (2021). Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies. MedRxiv, 2021.04.02.21254838. https://doi.org/10.1101/2021.04.02.21254838 Cite
Gearin, A. K., & Devenot, N. (2021). Psychedelic medicalization, public discourse, and the morality of ego dissolution. International Journal of Cultural Studies, 13678779211019424. https://doi.org/10.1177/13678779211019424 Cite
Guimarães, M. C., Guimarães, T. M., Hallak, J. E., Abrão, J., Machado-de-Sousa, J. P., Guimarães, M. C., Guimarães, T. M., Hallak, J. E., Abrão, J., & Machado-de-Sousa, J. P. (2021). Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial. Brazilian Journal of Psychiatry, AHEAD. https://doi.org/10.1590/1516-4446-2020-1543 Cite
Gukasyan, N., & Nayak, S. M. (2021). Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Transcultural Psychiatry, 1363461520983684. https://doi.org/10.1177/1363461520983684 Cite
Hendricks, P. S. (2018). Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. International Review of Psychiatry (Abingdon, England), 30(4), 331–342. https://doi.org/10.1080/09540261.2018.1474185 Cite
Illingworth, B. J., Lewis, D. J., Lambarth, A. T., Stocking, K., Duffy, J. M., Jelen, L. A., & Rucker, J. J. (2020). A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis. Journal of Psychopharmacology, 0269881120965915. https://doi.org/10.1177/0269881120965915 Cite
James, E., Robertshaw, T. L., Hoskins, M., & Sessa, B. (n.d.). Psilocybin occasioned mystical-type experiences. Human Psychopharmacology: Clinical and Experimental, n/a(n/a), e2742. https://doi.org/10.1002/hup.2742 Cite
Johnson, M. W. (2020). Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.0c00198 Cite
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83–102. https://doi.org/10.1016/j.pharmthera.2018.11.010 Cite
Kraehenmann, R. (2017). Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. Current Neuropharmacology, 15(7), 1032–1042. https://doi.org/10.2174/1573413713666170619092629 Cite
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020). Reviewing the Potential of Psychedelics for the Treatment of PTSD. International Journal of Neuropsychopharmacology, 23(6), 385–400. https://doi.org/10.1093/ijnp/pyaa018 Cite
Kuypers, K. P. C. (2020). The therapeutic potential of microdosing psychedelics in depression. Therapeutic Advances in Psychopharmacology, 10, 2045125320950567. https://doi.org/10.1177/2045125320950567 Cite
Luhrmann, T. M., Weisman, K., Aulino, F., Brahinsky, J. D., Dulin, J. C., Dzokoto, V. A., Legare, C. H., Lifshitz, M., Ng, E., Ross-Zehnder, N., & Smith, R. E. (2021). Sensing the presence of gods and spirits across cultures and faiths. Proceedings of the National Academy of Sciences, 118(5), e2016649118. https://doi.org/10.1073/pnas.2016649118 Cite
Majić, T., Schmidt, T. T., & Gallinat, J. (2015). Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Journal of Psychopharmacology, 29(3), 241–253. https://doi.org/10.1177/0269881114568040 Cite
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T., Müller, F., Tse, D. H. Y., Da Rios, B., Toennes, S. W., Stiers, P., Feilding, A., & Ramaekers, J. G. (2021). Spontaneous and deliberate creative cognition during and after psilocybin exposure. Translational Psychiatry, 11(1), 1–13. https://doi.org/10.1038/s41398-021-01335-5 Cite
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018). Psychedelics, Meditation, and Self-Consciousness. Frontiers in Psychology, 9. https://doi.org/10.3389/fpsyg.2018.01475 Cite
Morris, L. S., Costi, S., Tan, A., Stern, E. R., Charney, D. S., & Murrough, J. W. (2020). Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology, 45(6), 975–981. https://doi.org/10.1038/s41386-019-0591-5 Cite
Netzband, N., Ruffell, S., Linton, S., Tsang, W. F., & Wolff, T. (2020). Modulatory effects of ayahuasca on personality structure in a traditional framework. Psychopharmacology, 237(10), 3161–3171. https://doi.org/10.1007/s00213-020-05601-0 Cite
Nigam, K. B., & Pandurangi, A. K. (2021). Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature. SN Comprehensive Clinical Medicine. https://doi.org/10.1007/s42399-021-00871-x Cite
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369(9566), 1047–1053. https://doi.org/10.1016/S0140-6736(07)60464-4 Cite
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021). Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.1c00034 Cite
Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F. (2021). Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduction Journal, 18(1), 40. https://doi.org/10.1186/s12954-021-00489-1 Cite
Polito, V., & Stevenson, R. J. (2019). A systematic study of microdosing psychedelics. PloS One, 14(2), e0211023. https://doi.org/10.1371/journal.pone.0211023 Cite
Preller, K. H., & Vollenweider, F. X. (2018). Phenomenology, Structure, and Dynamic of Psychedelic States. Current Topics in Behavioral Neurosciences, 36, 221–256. https://doi.org/10.1007/7854_2016_459 Cite
Preller, K. H., & Vollenweider, F. X. (2018). Phenomenology, Structure, and Dynamic of Psychedelic States. In A. L. Halberstadt, F. X. Vollenweider, & D. E. Nichols (Eds.), Behavioral Neurobiology of Psychedelic Drugs (pp. 221–256). Springer. https://doi.org/10.1007/7854_2016_459 Cite
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., & McDonald, W. M. (2020). Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry, 177(5), 391–410. https://doi.org/10.1176/appi.ajp.2019.19010035 Cite
Ritchie, H., & Roser, M. (2018). Urbanization. Our World in Data. https://ourworldindata.org/urbanization Cite
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Frontiers in Pharmacology, 8. https://doi.org/10.3389/fphar.2017.00974 Cite
Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., & Mennenga, S. E. (2021). Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.1c00020 Cite
Rothberg, R. L., Azhari, N., Haug, N. A., & Dakwar, E. (2021). Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. Journal of Psychopharmacology, 35(2), 150–158. https://doi.org/10.1177/0269881120970879 Cite
Ruffell, S. (2018). A phenomenology of subjectively relevant experiences induced by ayahuasca in upper Amazonas vegetalismo tourism. Cite
Ruffell, S., Netzband, N., Tófoli, L. F., Rucker, J., Young, A., & Morgan, C. (2018). Ayahuasca induced effects on recall and reprocessing of childhood trauma, comorbid symptomology and biological markers in a traditional setting. Cite
Ruffell, S., Netzband, N., Young, A., & Juruena, M. (2018). The synergistic pharmacological interaction of compounds present in Ayahuasca: A Systematic review. Cite
Ruffell, S., Netzband, N., Bird, C., Young, A. H., & Juruena, M. F. (2020). The pharmacological interaction of compounds in ayahuasca: a systematic review. Brazilian Journal of Psychiatry, 42, 646–656. https://doi.org/10.1590/1516-4446-2020-0884 Cite
Simonsson, O., Sexton, J. D., & Hendricks, P. S. (2021). Associations between lifetime classic psychedelic use and markers of physical health. Journal of Psychopharmacology, 0269881121996863. https://doi.org/10.1177/0269881121996863 Cite
Smith, E. D. (1988). Evolving Ethics in Psychedelic Drug Taking. Journal of Drug Issues, 18(2), 201–214. https://doi.org/10.1177/002204268801800207 Cite
Smith, W. R., & Sisti, D. (2020). Ethics and ego dissolution: the case of psilocybin. Journal of Medical Ethics. https://doi.org/10.1136/medethics-2020-106070 Cite
Stauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021). Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience. ACS Pharmacology & Translational Science, 4(2), 526–532. https://doi.org/10.1021/acsptsci.0c00169 Cite
Tupper, K. W. (n.d.). Entheogenic Healing: The Spiritual Effects And Therapeutic Potential Of Ceremonial Ayahuasca Use. 20. Cite

Zapisz się do newslettera, aby otrzymywać najnowsze informacje.

Obrazek: Image by Gerd Altmann from Pixabay